NORTH BILLERICA, Mass.--(BUSINESS WIRE)--Feb. 27, 2018--
Lantheus Holdings, Inc. (the “Company”) (NASDAQ: LNTH), the parent
company of Lantheus Medical Imaging, Inc. (“LMI”), a global leader in
the development, manufacture and commercialization of innovative
diagnostic imaging agents, today announced the appointments of Gary J.
Pruden, Kenneth J. Pucel and Dr. James H. Thrall as members of its Board
of Directors, effective as of February 26, 2018. The Company’s Board of
Directors now consists of ten members.
Gary Pruden, who will serve as a member of the Audit Committee and the
Financing and Strategy Committee, has over 30 years of experience in the
global healthcare industry. Mr. Pruden held a number of senior
commercial leadership positions across both the medical device and
pharmaceutical sectors of Johnson & Johnson (“J&J”) from 1985 until
2017, including as a member of the Executive Committee of J&J, where his
official title was Executive Vice President, Worldwide Chairman, Medical
Ken Pucel, who will serve as a member of the Compensation Committee, has
been the Executive Vice President of Global Operations, Engineering &
Lean, at Polaris Industries Inc. since December 1, 2014. Previously, Mr.
Pucel was with Boston Scientific Corporation (“BSC”), a global provider
of medical solutions, where he held positions of increasing
responsibility, most recently as Executive Vice President of Global
Operations, Quality and Technology from 2012 through 2014, and as a
member of BSC’s Executive Committee from 2004 through 2014.
Dr. Jim Thrall, who will serve as a member of the Nominating and
Corporate Governance Committee, currently holds the Juan M. Taveras
Professorship of Radiology at Harvard Medical School, having also served
as Chairman of the Department of Radiology at the Massachusetts General
Hospital from 1988 until 2013. Dr. Thrall is also a member of the
National Academy of Medicine and has served in leadership and board of
directors positions at many U.S. and international medical and
“We welcome Gary, Ken and Jim to the Board,” said Mary Anne Heino,
President and CEO. “Each of our new directors will, in his own
individual way, be able to contribute significantly to our corporate
growth strategy,” said Mary Anne Heino, President and CEO. “Gary brings
to us global pharmaceutical experience, including in the strategy,
operations, business development and regulatory areas, making him
uniquely suited to this growth phase of our Company. Ken’s expertise in
manufacturing, supply chain and distribution will prove invaluable as we
build out additional specialized manufacturing capabilities and expand
our product offerings. Jim’s intimate knowledge of nuclear medicine,
radiology and clinical practice will further strengthen our ability to
lead the next generation of diagnostic imaging. With these new
directors, our Company’s capabilities are stronger than ever.”
About Lantheus Holdings, Inc. and Lantheus Medical Imaging, Inc.
Lantheus Holdings, Inc. is the parent company of Lantheus Medical
Imaging, Inc. (“LMI”), a global leader in the development, manufacture
and commercialization of innovative diagnostic imaging agents and
products. LMI provides a broad portfolio of products, including the
echocardiography contrast agent DEFINITY® Vial for
(Perflutren Lipid Microsphere) Injectable Suspension; TechneLite®
(Technetium Tc99m Generator), a technetium-based generator that provides
the essential medical isotope used in nuclear medicine procedures; and
Xenon (Xenon Xe 133 Gas), an inhaled radiopharmaceutical imaging agent
used to evaluate pulmonary function and for imaging the lungs. The
Company is headquartered in North Billerica, Massachusetts with offices
in Puerto Rico and Canada. For more information, visit www.lantheus.com.
Safe Harbor for Forward-Looking and Cautionary Statements
This press release contains “forward-looking statements” as defined
under U.S. federal securities laws. Forward-looking statements are
subject to risks and uncertainties that could cause actual results to
materially differ from those described in the forward- looking
statements. Readers are cautioned not to place undue reliance on the
forward-looking statements contained herein, which speak only as of the
date hereof. The Company undertakes no obligation to publicly update any
forward-looking statement, whether as a result of new information,
future developments or otherwise, except as may be required by law.
Risks and uncertainties that could cause our actual results to
materially differ from those described in the forward-looking statements
are discussed in our filings with the Securities and Exchange Commission
(including those described in the Risk Factors section in our Annual
Reports on Form 10-K and our Quarterly Reports on Form 10-Q).
View source version on businesswire.com: http://www.businesswire.com/news/home/20180227005931/en/
Source: Lantheus Holdings, Inc.
Lantheus Holdings, Inc.
Meara Murphy, 978-671-8508
Investor Relations & Corporate Communications